布雷德尼松-硫化释放混合体显示在喘中改善了治疗特征
Ida Cerqua1, Elisabetta Granato1, Angela Corvino1
1Department of Pharmacy, School of Medicine and Surgery, University of Naples Federico II, Naples, Campania, Italy.
Frontiers in pharmacology
|October 30, 2023
概括
一种新的组合疗法,与硫化 (H2S) 供体结合的普雷尼松,通过减少呼吸道炎症和过度反应,有效地控制喘. 这种新的治疗优化了对呼吸道炎症疾病的皮质类固醇益处.
科学领域:
- 生物医学科学 生物医学科学
- 药理学 药理学是指药理学的学科.
- 呼吸系统医学 呼吸系统医学
背景情况:
- 硫化 (H2S) 对呼吸道炎症性疾病具有治疗潜力.
- 皮质类固醇是标准的喘治疗方法,但也有局限性.
- 需要新的药物输送系统来提高治疗疗效.
研究的目的:
- 研究一种与H2S捐赠体 (PS-TBZ) 化学连接的新型皮质类固醇衍生物在治疗喘方面的有效性.
- 评估普得尼松 (PS) 和H2S供体 (TBZ) 对喘特征的联合作用.
主要方法:
- 在体外研究中,使用脂多糖刺激的J774巨细胞.
- 在活体研究中,在卵胺敏感的BALB/c小鼠中使用实验性喘模型.
- 评估炎症调解剂,支气管收缩性,气道过敏反应和气道重塑标记物 (α-SMA,三号公原).
主要成果:
- 与实验室中的单个成分相比,PS-TBZ证明了炎症媒介的增强调节.
- 在体内,PS-TBZ显著降低了气道过敏反应,改善了支气管放松.
- PS-TBZ通过减少α-SMA和公原III有效控制了气道重塑,促进了上皮细胞的修复,并抑制了粘素的产生.
结论:
- 新的PS-TBZ化合物提供了一种优化的方法来治疗喘的皮质类固醇治疗.
- PS-TBZ为控制喘和其他呼吸道炎症疾病的特征提供了一个有前途的治疗策略.
- 这种组合疗法增强了皮质类固醇的有益作用,这表明了喘治疗的新途径.
相关概念视频
Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids
273
Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...
273
Asthma-IV: Diagnostic and Management
2.5K
The diagnosis and management of asthma are comprehensive, encompassing clinical assessments, lung function tests, and pharmacological interventions. Here's an overview:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
Clinical Assessment for Asthma:
This is the first step in diagnosing and managing asthma. It includes:
2.5K
Inhaled Medications
288
Inhaled medications are crucial for managing chronic obstructive pulmonary disease (COPD) and asthma. They are essential for effective treatment and control, ensuring optimal respiratory health and well-being. Inhaled medication delivers drugs directly to the lungs, providing a rapid onset of action and reducing systemic side effects compared to oral or injectable medications. Three primary types of inhalation devices are used to administer these medications: nebulizers, metered-dose inhalers...
288
COPD: Management Using Bronchodilators and Corticosteroids
217
Chronic obstructive pulmonary isease (COPD) involves a group of progressive lung disorders characterized by persistent airflow limitation and chronic respiratory symptoms. Asthma-COPD Overlap Syndrome (ACOS), encompassing features of both asthma and Chronic obstructive pulmonary disease (COPD), is a group of progressive lung disorders that includes chronic bronchitis, emphysema, and refractory (non-reversible) asthma. ACOS leads to complex clinical presentations that combine the inflammatory...
217
Antiasthma Drugs: β2-Adrenoceptor Agonists
278
Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...
278
Drugs Used in Lower Respiratory Disorders: Overview
458
Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
458


